Replies to post #14781 on Amarin Corp Plc (AMRN)

[drrc1949]

With enrollment for the Reduce-It Trial at 75%, it's already a huge plus for investors....although in the near term not so fortunate for enrollees. It means that overall cardiac events will really start to accelerate and begin approaching the outcomes limit. That could drag the trial's ending date forward and ultimately, the sooner results are achieved, the better for everyone. The indications on Vascepa expand for the benefit of all cardiac sufferers and as investors, we finally get a good night's sleep!

[BioChica]

Yes the planets are aligning in our favor. Well if the control arm has a much larger number of recorded events, heart failure/deaths. It's possible the trial could be closed earlier then expected. The control arm patient's would then continue treatment on Vascepa. Let's hope this 4 gram dose works that well.

We can both live the rest of our lives, with some money in the bank.

Did they mention unblinding the trial at anytime? Allowing a outside panel to evaluate the preliminary study results?

I have seen this done in a number of cancer drug trials.